广西医学
廣西醫學
엄서의학
GUANGXI MEDICAL JOURNAL
2014年
8期
1089-1092
,共4页
2型糖尿病%罗格列酮%胰岛素%输注泵%血管内皮功能
2型糖尿病%囉格列酮%胰島素%輸註泵%血管內皮功能
2형당뇨병%라격렬동%이도소%수주빙%혈관내피공능
Type 2 diabetes mellitus%Rosiglitazone%Insulin%Infusion pump%Vascular endothelial function
目的:探讨罗格列酮联合胰岛素泵( CSⅡ)强化治疗2型糖尿病的疗效及对患者血管内皮功能的影响。方法选择2型糖尿病患者84例,按随机数表法将患者分为观察组和对照组各42例。观察组采用罗格列酮联合CSⅡ治疗,对照组采用CSⅡ治疗。连续治疗2周后观察两组患者疗效、血管内皮依赖性舒张功能( EDD)变化、血糖达标时间、胰岛素用量以及不良反应发生情况。结果两组患者治疗后空腹血糖、餐后2h血糖、总胆固醇(TC)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR)均较治疗前显著降低,胰岛素敏感指数(ISI)较治疗前显著升高(P均<0.05);而两组患者体重指数、甘油三酯、高密度脂蛋白、低密度脂蛋白治疗前后无显著变化(P>0.05)。治疗后,观察组TC、HbA1 c、HOMA-IR均显著低于对照组(P均<0.05)。两组患者治疗后EDD均较治疗前显著升高(P<0.05);治疗后,观察组EDD显著高于对照组(P<0.05)。观察组血糖达标时间以及胰岛素用量均显著低于对照组(P<0.05),两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论罗格列酮联合胰岛素泵强化治疗更能有效减轻2型糖尿病患者胰岛素抵抗,改善患者血管内皮功能,且不良反应少。
目的:探討囉格列酮聯閤胰島素泵( CSⅡ)彊化治療2型糖尿病的療效及對患者血管內皮功能的影響。方法選擇2型糖尿病患者84例,按隨機數錶法將患者分為觀察組和對照組各42例。觀察組採用囉格列酮聯閤CSⅡ治療,對照組採用CSⅡ治療。連續治療2週後觀察兩組患者療效、血管內皮依賴性舒張功能( EDD)變化、血糖達標時間、胰島素用量以及不良反應髮生情況。結果兩組患者治療後空腹血糖、餐後2h血糖、總膽固醇(TC)、糖化血紅蛋白(HbA1c)、胰島素牴抗指數(HOMA-IR)均較治療前顯著降低,胰島素敏感指數(ISI)較治療前顯著升高(P均<0.05);而兩組患者體重指數、甘油三酯、高密度脂蛋白、低密度脂蛋白治療前後無顯著變化(P>0.05)。治療後,觀察組TC、HbA1 c、HOMA-IR均顯著低于對照組(P均<0.05)。兩組患者治療後EDD均較治療前顯著升高(P<0.05);治療後,觀察組EDD顯著高于對照組(P<0.05)。觀察組血糖達標時間以及胰島素用量均顯著低于對照組(P<0.05),兩組患者不良反應髮生率比較,差異無統計學意義(P>0.05)。結論囉格列酮聯閤胰島素泵彊化治療更能有效減輕2型糖尿病患者胰島素牴抗,改善患者血管內皮功能,且不良反應少。
목적:탐토라격렬동연합이도소빙( CSⅡ)강화치료2형당뇨병적료효급대환자혈관내피공능적영향。방법선택2형당뇨병환자84례,안수궤수표법장환자분위관찰조화대조조각42례。관찰조채용라격렬동연합CSⅡ치료,대조조채용CSⅡ치료。련속치료2주후관찰량조환자료효、혈관내피의뢰성서장공능( EDD)변화、혈당체표시간、이도소용량이급불량반응발생정황。결과량조환자치료후공복혈당、찬후2h혈당、총담고순(TC)、당화혈홍단백(HbA1c)、이도소저항지수(HOMA-IR)균교치료전현저강저,이도소민감지수(ISI)교치료전현저승고(P균<0.05);이량조환자체중지수、감유삼지、고밀도지단백、저밀도지단백치료전후무현저변화(P>0.05)。치료후,관찰조TC、HbA1 c、HOMA-IR균현저저우대조조(P균<0.05)。량조환자치료후EDD균교치료전현저승고(P<0.05);치료후,관찰조EDD현저고우대조조(P<0.05)。관찰조혈당체표시간이급이도소용량균현저저우대조조(P<0.05),량조환자불량반응발생솔비교,차이무통계학의의(P>0.05)。결론라격렬동연합이도소빙강화치료경능유효감경2형당뇨병환자이도소저항,개선환자혈관내피공능,차불량반응소。
Objective To investigate the curative effect of rosiglitazone combined with insulin pump ( CSⅡ) and the influence on vascular endothelial function in patients with type 2 diabetes mellitus(T2DM).Methods Eighty-four patients with T2DM were randomly divided into observation group and control group ,with 42 cases in each group .The patients in the control group were treated with CSⅡ,while the patients in the observation group were treated with rosiglitazone combined with CSⅡ.The treatment lasted for 2 weeks.The curative effect ,changes in vascular endothelium-dependent relaxing function(EDD),time of blood glucose control in target,dosage of insulin,and adverse reactions occurring were observed in both groups.Results Fasting blood glucose(FBG),postprandial 2 hours blood glucose(2hPG),total cholesterol(TC),glycosylated hemoglobin(HbA1c),insulin resistance index(HOMA-IR) in two groups after treatment were significantly lower than those before treatment ( all P <0 .05 ) , while insulin sensitivity index ( ISI ) after treatment increased significantly ( P<0 .05 ) .No significant difference was observed in body mass index ( BMI ) , triglyceride ( TG ) , high-density lipoprotein(HDL),low-density lipoprotein(LDL) before and after treatment(P>0.05).After treatment,TC,HbA1c and HOMA-IR in the observation group were significantly lower than those in the control group (all P<0.05).EDD in two groups after treatment was significantly higher than that before treatment (P<0.05),and EDD in the observation group was significantly higher than that in the control group after treatment ( P<0 .05 ) .The time of blood glucose control in target and insulin dosage in the observation group were significantly lower than those in the control group (P<0.05),there was no significant difference in the incidence of adverse reactions between two groups (P>0.05). Conclusion Rosiglitazone combined with insulin pump can relieve insulin resistance more effectively in patients with T2DM and improve the function of vascular endothelial .The adverse reactions are few .